Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Upadacitinib (ABT-494) 是高效选择性的,具有口服活性的 JAK1抑制剂,IC50为43 nM,可用于多种自身免疫性疾病的研究。它对 JAK1 的选择性约为 JAK2 的 74 倍。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 333 | 现货 | ||
2 mg | ¥ 482 | 现货 | ||
5 mg | ¥ 777 | 现货 | ||
10 mg | ¥ 1,160 | 现货 | ||
25 mg | ¥ 2,430 | 现货 | ||
50 mg | ¥ 3,550 | 现货 | ||
100 mg | ¥ 5,130 | 现货 | ||
200 mg | ¥ 6,920 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 659 | 现货 |
产品描述 | Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM. |
靶点活性 | JAK2:200 nM, JAK1:43 nM |
体外活性 | Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2, which is involved in erythropoiesis. And Upadacitinib is 58-fold more selective for JAK-1 than for JAK-3, which is involved in immunosurveillance. The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit-risk profile in patients with RA range. |
体内活性 | Upadacitinib, a second JAK inhibitor, has been developed by AbbVie.Upadacitinib finished multiple-dose Phase I studies in 2013. Upadacitinib show to be safe and well-tolerated up to multiple doses of 24 mg twice daily using the immediate release formulation in phase I trials. Upadacitinib exposure is dose proportional to the evaluated multiple dose. |
别名 | 乌帕替尼, ABT-494 |
分子量 | 380.37 |
分子式 | C17H19F3N6O |
CAS No. | 1310726-60-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (144.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.629 mL | 13.1451 mL | 26.2902 mL | 65.7255 mL |
5 mM | 0.5258 mL | 2.629 mL | 5.258 mL | 13.1451 mL | |
10 mM | 0.2629 mL | 1.3145 mL | 2.629 mL | 6.5725 mL | |
20 mM | 0.1315 mL | 0.6573 mL | 1.3145 mL | 3.2863 mL | |
50 mM | 0.0526 mL | 0.2629 mL | 0.5258 mL | 1.3145 mL | |
100 mM | 0.0263 mL | 0.1315 mL | 0.2629 mL | 0.6573 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Upadacitinib 1310726-60-3 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK ABT 494 inhibit Inhibitor autoimmune orally active 乌帕替尼 JAK1 ABT-494 Janus kinase ABT494 inhibitor